

Affinium Pharmaceuticals (Toronto, Ontario, Canada) has announced the appointment of **Christian Burks** as chief scientific officer. Dr. Burks was most recently vice president and chief informatics officer at Exelixis.

OXiGENE (Watertown, MA) has appointed **Frederick Driscoll** as CEO, replacing **Bjorn Nordenvall**. Dr. Nordenvall will remain on the board of directors as vice chairman and serve as a strategic consultant to the company. Prior to joining OXiGENE as president and CFO in October 2000, Mr. Driscoll served as senior vice president of finance and operations at Collagenesis.

CuraGen (New Haven, CT) has announced the elections of **David R. Ebsworth** and **John H. Forsgren** to its board of directors. Dr. Ebsworth was formerly president and general manager of the pharmaceutical business group for Bayer AG, and Mr. Forsgren is vice chairman of the board and CFO of Northeast Utilities. In addition, **Richard H. Booth**, CEO of HSB Group, has stepped down from CuraGen's board, but will remain an advisor to the company.

Rigel Pharmaceuticals (S. San Francisco, CA) has announced the appointment of **Elliott Grossbard** as senior vice president of medical development. Prior to joining Rigel, Dr. Grossbard was vice president, clinical affairs for Avigen.

**Wayne T. Hockmeyer** has been elected to the board of directors of Novirio Pharmaceuticals (Cambridge, MA). Dr. Hockmeyer founded MedImmune in 1988, served as its president and CEO until October 2000, and is currently chairman of its board of directors.

**Neil Kurtz** has been named president, CEO, and a board member of Neurogenetics (La Jolla, CA). Dr. Kurtz was previously president at Ingenix Pharmaceutical Services, a division of United Healthcare Group, and a cofounder, president, and CEO of Worldwide Clinical Trials.

Therion Biologics (Cambridge, MA) has announced the appointment of **Mark Leuchtenberger** as president and CEO. Mr. Leuchtenberger joins the company from Biogen, where he served most recently as vice president, international. **Dennis L. Panicali**, who founded Therion and has served as president and CEO for the last 11 years, will serve as the company's first chief scientific officer and will also remain a member of the board of directors.

Amgen (Thousand Oaks, CA) has announced that **Joseph P. Miletich** has

joined the company as senior vice president, research and preclinical development. Dr. Miletich was most recently senior vice president for worldwide preclinical development at Merck Research Laboratories.

Gilead Sciences (Foster City, CA) has named **John F. Milligan** senior vice president and CFO. Dr. Milligan joined Gilead in 1990 and served most recently as vice president, corporate development. **Sharon Surrey-Barbari**, who joined Gilead in 1998 and has served as vice president and CFO since February 2000, has announced her resignation from the company.

Orchid BioSciences (Princeton, NJ) has appointed **Kenneth D. Noonan** to its board of directors to replace Anne VanLent, who resigned in 2001. Dr. Noonan is a partner at LEK Consulting and leads the firm's life sciences practice in the UK and Europe. Prior to joining LEK, Dr. Noonan was senior vice president of corporate development for Applera Corp.

**Jean O'Connor** has been named to the newly created position of vice president, quality assurance at Genta (Berkeley Heights, NJ). She comes to the company after more than 20 years at Johnson & Johnson, where she held positions of increasing responsibility in regulatory affairs and quality assurance within numerous divisions including the R.W. Johnson Pharmaceutical Research Institute, Ortho Biotech, and Ortho Diagnostics.

**Michael S. Richman** has joined MacroGenics (Rockville, MD) as executive vice president and chief operating officer. He was formerly senior vice president of corporate development and administration at MedImmune. In addition, MacroGenics has named **Kathryn E. Stein** as vice president for product development and regulatory affairs. Dr. Stein has been a member of the Center for Biologics Evaluation and Research (CBER) at the US FDA since 1980 and has served as director of the division of monoclonal antibodies since its inception in 1992.



**Marc Vasseur** has been named senior vice president of Genset (Paris), with responsibility for the development of strategic projects in the central nervous system field. Mr.

Vasseur cofounded Genset in 1989 and served as chief biology officer until July 2000. In August 2000, he founded Pasteur Mediavita, a life-science multimedia publishing company, and held the position of CEO until March 2002.